Download PDF
CC BY-NC-ND 4.0 · Indian J Plast Surg 2022; 55(02): 149-155
DOI: 10.1055/s-0042-1749406
Review Article

Endocrine Therapy of Adult Gender-Incongruent Individuals Seeking Gender Reaffirmation

Anirban Majumder 
1   Department of Endocrinology, KPC Medical College and Hospital, Kolkata, West Bengal, India
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Gender-affirming hormone therapy (GAHT) is integral to the management of gender-incongruent (GI) individuals. GAHT greatly improves the quality of life for GI individuals. Current research about outcomes of GAHT and adverse events in adults receiving GAHT is limited in India and large cohort studies are absent. This document on medical management provides protocols for the prescribing clinician relating to counseling for GAHT, baseline evaluation, choice of therapy, targets for hormone therapy, clinical and biochemical monitoring, and perioperative hormone therapy.

Keywords

gender-affirming hormone therapy - gender incongruent - transfeminine - transmasculine - transgender - hormone therapy


Publication History

Article published online:
05 July 2022

© 2022. Association of Plastic Surgeons of India. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sanyal D, Majumder A. Presentation of gender dysphoria: a perspective from eastern India. Indian J Endocrinol Metab 2016; 20 (01) 129-133
    CrossrefPubMedGoogle Scholar
  • 2 Hembree WC, Cohen-Kettenis PT, Gooren L. et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102 (11) 3869-3903 [published correction appears in J Clin Endocrinol Metab. 2018 Feb 1;103(2):699] [published correction appears in J Clin Endocrinol Metab. 2018 Jul 1;103(7):2758–2759]
    CrossrefPubMedGoogle Scholar
  • 3 Majumder A, Sanyal D. Outcome and preferences in male-to-female subjects with gender dysphoria: experience from eastern India. Indian J Endocrinol Metab 2017; 21 (01) 21-25
    CrossrefPubMedGoogle Scholar
  • 4 Majumder A, Sanyal D. Outcome and preferences in female-to-male subjects with gender dysphoria: experience from eastern India. Indian J Endocrinol Metab 2016; 20 (03) 308-311
    CrossrefPubMedGoogle Scholar
  • 5 Barrett J. Gender dysphoria: assessment and management for non-specialists. BMJ 2017; 357: j2866 DOI: 10.1136/bmj.j2866.
    CrossrefPubMedGoogle Scholar
  • 6 Majumder A, Chatterjee S, Maji D. et al. IDEA Group consensus statement on medical management of adult gender incongruent individuals seeking gender reaffirmation as female. Indian J Endocrinol Metab 2020; 24 (02) 128-135
    CrossrefPubMedGoogle Scholar
  • 7 Iwamoto SJ, Defreyne J, Rothman MS. et al. Health considerations for transgender women and remaining unknowns: a narrative review. Ther Adv Endocrinol Metab 2019; 10: 2042018819871166 DOI: 10.1177/2042018819871166.
    CrossrefPubMedGoogle Scholar
  • 8 Leinung MC, Feustel PJ, Joseph J. Hormonal treatment of transgender women with oral estradiol. Transgend Health 2018; 3 (01) 74-81
    CrossrefPubMedGoogle Scholar
  • 9 Unger CA. Hormone therapy for transgender patients. Transl Androl Urol 2016; 5 (06) 877-884
    CrossrefPubMedGoogle Scholar
  • 10 Safer JD, Tangpricha V. Care of transgender persons. N Engl J Med 2019; 381 (25) 2451-2460
    CrossrefPubMedGoogle Scholar
  • 11 Prior JC. Progesterone is important for transgender women's therapy-applying evidence for the benefits of progesterone in ciswomen. J Clin Endocrinol Metab 2019; 104 (04) 1181-1186
    CrossrefPubMedGoogle Scholar
  • 12 T'Sjoen G, Arcelus J, Gooren L, Klink DT, Tangpricha V. Endocrinology of transgender medicine. Endocr Rev 2019; 40 (01) 97-117
    CrossrefPubMedGoogle Scholar
  • 13 Jain J, Kwan D, Forcier M. Medroxyprogesterone acetate in gender-affirming therapy for transwomen: results from a retrospective study. J Clin Endocrinol Metab 2019; 104 (11) 5148-5156
    CrossrefPubMedGoogle Scholar
  • 14 Ginsberg BA. Dermatologic care of the transgender patient. Int J Womens Dermatol 2016; 3 (01) 65-67
    CrossrefPubMedGoogle Scholar
  • 15 Pelusi C, Costantino A, Martelli V. et al. Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med 2014; 11 (12) 3002-3011
    CrossrefPubMedGoogle Scholar
  • 16 Sterling J, Garcia MM. Cancer screening in the transgender population: a review of current guidelines, best practices, and a proposed care model. Transl Androl Urol 2020; 9 (06) 2771-2785
    CrossrefPubMedGoogle Scholar
  • 17 Singh V, Gratzer B, Gorbach PM. et al. Transgender women have higher human papillomavirus prevalence than men who have sex with men-two U.S. cities, 2012-2014. Sex Transm Dis 2019; 46 (10) 657-662
    CrossrefPubMedGoogle Scholar
  • 18 Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2019; 68 (32) 698-702
    CrossrefPubMedGoogle Scholar